Gain Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +32.0% | -21.7% | +31.7% | -25.2% | -15.6% | -4.1% | -15.4% | +11.6% | +108.0% | -17.9% | -17.7% | |
| – | +34.3% | -22.0% | +33.7% | -25.9% | -15.6% | -3.9% | -16.5% | +13.0% | +111.4% | -18.1% | -17.8% | |
| – | +176.1% | -9.8% | +59.2% | -28.9% | -13.8% | -12.7% | -26.2% | +31.6% | +136.6% | -20.6% | -20.9% | |
| – | +37.3% | -24.6% | +33.8% | -28.9% | -13.8% | -12.7% | -26.2% | +31.6% | +136.6% | -20.6% | -20.9% | |
| – | +138.0% | +2.7% | +25.7% | +19.3% | +104.9% | +15.8% | +59.5% | -44.2% | +1.8% | +23.9% | -78.8% | |
| – | +2.2% | -12.5% | -6.6% | -1.2% | -14.1% | -5.9% | +1.2% | -10.4% | -10.3% | -12.4% | -14.7% | |
| – | -10.9% | -1.6% | +24.9% | -26.4% | -12.3% | +22.2% | +5.0% | -17.5% | -16.0% | +11.2% | -12.7% | |
| – | -14.1% | +1.1% | +30.4% | -29.6% | -14.9% | +28.6% | +3.4% | -19.8% | -19.6% | +15.9% | -11.6% | |
| – | +2.4% | -9.5% | -5.6% | -0.3% | -8.7% | -3.4% | +0.2% | -8.0% | -8.6% | -1.7% | +7.4% | |
| – | -4.2% | +6.5% | +45.7% | -46.3% | -13.9% | +127.4% | +26.1% | -41.9% | -47.7% | +83.8% | -19.5% | |
| – | +3.2% | -11.6% | -5.4% | +0.2% | -12.7% | -4.2% | +3.5% | -8.2% | +0.4% | -8.9% | -19.5% | |
| – | +71.6% | -31.3% | +36.4% | -24.4% | -17.6% | -21.3% | -36.1% | +59.9% | +214.2% | -24.6% | -19.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +27.6% | +10.9% | +6.9% | +38.1% | +2.3% | +5.7% | +5.8% | +15.3% | -5.8% | +28.1% | +1.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.